CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Abbott launches next-generation Oncodetect blood test to detect residual cancer

By Public Technologies
  • Abbott launched its next-generation Oncodetect molecular residual disease test on Oct. 26, 2026, for patients with solid tumors.
  • The blood test uses whole-genome sequencing to detect residual cancer during and following treatment, helping inform recurrence risk assessments.
  • Colorectal cancer study results already presented at ESMO showed improved detection of recurrence risk compared with the first-generation test.
  • Modeling estimates more than 3 million US patients could potentially benefit from MRD testing; more than 20 Oncodetect studies are ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610260900PR_NEWS_USPR_____CG80153) on October 26, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk